Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066690 · ClinicalTrials.gov registry record · Phase 3
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
A Phase 3 study, sponsored by ETOP IBCSG Partners Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,066
- Enrollment target
NCT00066690 is a Phase 3 study that has completed, run by ETOP IBCSG Partners Foundation. The registered enrollment target is 3,066 participants.
The verdict
NCT00066690, a Phase 3 study, has completed, sponsored by ETOP IBCSG Partners Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,066 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- RADIATION Radiation Therapy
- DRUG Exemestane
- PROCEDURE Oophorectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,066 participants |
| Start Date | 2003-12-17 |
| Est. Completion | 2024-11-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066690
The ClinicalTrials.gov registry entry for NCT00066690 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,066 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ETOP IBCSG Partners Foundation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT00066690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00066690 about?
NCT00066690 is a clinical study titled "Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxif...
What is the current status of trial NCT00066690?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,066 participants. The study started on 2003-12-17. Estimated completion is 2024-11-06.
What interventions are being tested in trial NCT00066690?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Radiation Therapy (RADIATION), Exemestane (DRUG), Oophorectomy (PROCEDURE).
Who is sponsoring clinical trial NCT00066690?
This trial is sponsored by ETOP IBCSG Partners Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.